Related Experiment Video
Updated: Apr 25, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
SENP5, a SUMO isopeptidase, induces apoptosis and cardiomyopathy
Eun Young Kim1, Yi Zhang2, Ilimbek Beketaev1
1Center for Stem Cell Engineering, Department of Basic Research Laboratories, Texas Heart Institute at St. Luke's Episcopal Hospital, 6770 Bertner Avenue, MC 2-255, Houston, TX 77030, USA.
Insights
The desumoylation enzyme SENP5 is elevated in failing hearts, causing cardiac dysfunction and apoptosis by affecting mitochondrial dynamics. Targeting the SUMO conjugation pathway may offer new treatments for cardiomyopathy.
Area of Science:
- Cardiovascular Biology
- Mitochondrial Biology
- Posttranslational Modifications
Background:
- Cardiomyopathy is a major cause of heart failure, with over 50% of cases being idiopathic.
- SUMOylation is a reversible posttranslational modification, but its role in heart disease is unknown.
- Sentrin-specific proteases (SENPs) reverse SUMOylation.
Purpose of the Study:
- To investigate the role of SENP5, a SUMO isopeptidase, in the pathogenesis of cardiac muscle disorders.
- To determine if SENP5 overexpression in cardiomyocytes leads to cardiac dysfunction.
Main Methods:
- Overexpression of SENP5 in murine cardiomyocytes (SENP5 transgenic, SENP5-Tg).
- Assessment of cardiac function, cardiomyocyte proliferation, and apoptosis.
- Analysis of SUMOylation of dynamin related protein (Drp1) and mitochondrial morphology.
Main Results:
- SENP5 levels were significantly increased in human idiopathic failing hearts.
- SENP5 overexpression in mice led to cardiac dysfunction, decreased cardiomyocyte proliferation, and increased apoptosis.
- SENP5-Tg hearts showed reduced SUMOylation of Drp1, enlarged mitochondria, and impaired mitochondrial fission.
- Overexpression of Bcl2 improved cardiac function in SENP5-Tg mice, indicating SENP5 targets mitochondrial function.
Conclusions:
- SENP5 plays a critical role in the development of cardiac muscle disorders.
- SENP5-induced desumoylation of Drp1 contributes to cardiomyopathy phenotypes.
- The SUMO conjugation pathway is a potential therapeutic target for cardiomyopathy.
Abstract:
Cardiomyopathy presents a major health issue and is a leading cause of heart failure. Although a subset of familial cardiomyopathy is associated with genetic mutations, over 50% of cardiomyopathy is defined as idiopathic, the mechanisms underlying which are under intensive investigation. SUMO conjugation is a dynamic posttranslational modification that can be readily reversed by the activity of sentrin-specific proteases (SENPs). However, whether SENPs are implicated in heart disease pathophysiology remains unexplored. We observed a significant increase in the level of SENP5, a SUMO isopeptidase, in human idiopathic failing hearts. To reveal whether it plays a role in the pathogenesis of cardiac muscle disorders, we used a gain-of-function approach to overexpress SENP5 in murine cardiomyocytes (SENP5 transgenic, SENP5-Tg). Overexpression of SENP5 led to cardiac dysfunction, accompanied by decreased cardiomyocyte proliferation and elevated apoptosis. The increase in apoptosis preceded other detectable pathological changes, suggesting its causal link to cardiomyopathy. Further examination of SENP5-Tg hearts unveiled a decrease in SUMO attachment to dynamin related protein (Drp1), a factor critical for mitochondrial fission. Correspondingly, the mitochondria of SENP5-Tg hearts at an early developmental stage were significantly larger compared with those in the control hearts, suggesting that desumoylation of Drp1 at least partially accounts for the cardiac phenotypes observed in the SENP5-Tg mice. Finally, overexpression of Bcl2 in SENP5-Tg hearts improved cardiac function of SENP5-Tg mice, further supporting the notion that SENP5 mainly targets mitochondrial function in vivo. Our findings demonstrate an important role of the desumoylation enzyme SENP5 in the development of cardiac muscle disorders, and point to the SUMO conjugation pathway as a potential target in the prevention/treatment of cardiomyopathy. This article is part of a Special Issue entitled "Mitochondria: From Basic Mitochondrial Biology to Cardiovascular Disease".
Related Concept Videos
Caspases
Cellular Injury V: Apoptosis and Autophagy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Apoptosis

